GenOMICC UK Virtual Site Visit
COVID-19 is a key aim of GenOMICC
Susceptibility to COVID-19 is almost certainly, in part, genetic. GenOMICC can find the genes that cause susceptibility, which may help us to prioritise treatments to respond to the global crisis.
GenOMICCwas designed for this crisis. Since 2016, the open, global GenOMICC collaboration has been recruit patients with emerging infections, including COVID-19. All patients with confirmed COVID-19 in critical care are eligible for GenOMICC; please recruit them as normal, following local infection control precautions.
In particular, we aim to recruit every intubated patient with COVID-19. If you need to prioritise, please start with the youngest.
GenOMICCis prioritised as an NIHR Urgent Public Health Study in the UK
In the UK, recruitment to
GenOMICCwill supplement other studies (e.g. ISARIC 4C, RECOVERY, and REMAP-CAP), enabling better prioritisation of treatments and faster answers. We will co-enrol and combine samples. Telephone consent is allowed, or witnessed consent forms (from outside the PPE area) can be used to record consent.
Thanks for obtaining approval to recruit to the
Before you start, you should:
- be appropriately trained to conduct clinical research in patients in your clinical area and legal system
- have ethics and R&D approval for
- have access to the REDCap CRF at redcap.clinicaltrials.ed.ac.uk
You will need to create a GCP-compliant site file and store it in a secure location accessible only to trained staff working on the study. The site file should contain:
- Study Documents
- Research Team
- Safety reporting
- Protocol Violations
- Protocol Deviations
- Participant Documents
- Consent forms
Sample collection kits
- Sticky labels for each patient
- Sample bag and absorbent material
- Pre-addressed specimen boxes for postage
Identify eligible patients
The key objective of GenOMICC during COVID-19 is to recruit every intubated COVID-19 case. Other eligible conditions (such as Influenza, Pneumonia, Emerging infections, Burns, Vaping/CAR T-cell reactions, need for ECLS, Cellulitis, Pancreatitis) are listed in the inclusion criteria.
graph TD A[Intubated or
requiring continuous monitoring?] -->B B[COVID-19] --> Y A --> C C[Any other eligible diagnosis] --> D D[Free from
pre-existing disease] --> Y Y[Recruit patient to GenOMICC]
Obtain consent. For telephone consent, see the telephone consent script. Patients or relatives can be directed to the online patient information sheet.
Obtain blood sample according to the patient's weight (>40kg: 9mls; 20 to 40kg: 7mls; 10 to 20kg: 4mls). Blood can be obtained in any EDTA blood tubes. Depending on what system is used in your hospital, you will probably have to send us several tubes. Try to get as close as you can to the required volume, because this gives us the best chance of getting high-quality DNA.
Take all four of the of GenOMICC sample stickers from inside one of the return GenOMICC specimen boxes that we have sent to you.
Use the stickers to label the consent form and the blood tubes. Destroy any unused stickers.
Store consent form in local site file.
Put blood tubes in the plastic bag with absorbent material, seal and package into the GenOMICC postage - paid specimen box and return to the Wellcome Trust Clinical Reseach Facility (WTCRF), Edinburgh as soon as possible.
Complete RedCap CRF, including:
- Clinical and demographic details
- Positive microbiology (when available)
- 60 day outcome (when available)
For patients lacking capacity - plan a review date to assess for regained capacity.
Example blood tubes to use for a patient >40kg in weight. Please note that other volumes can be used.
|System||Tube size||Number of tubes||Total volume|
|Any EDTA blood tube||any size||<=9ml|